190 related articles for article (PubMed ID: 23857864)
1. Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia® (denosumab) for the treatment of postmenopausal osteoporosis.
Xue F; Ma H; Stehman-Breen C; Haller C; Katz L; Wagman RB; Critchlow CW;
Pharmacoepidemiol Drug Saf; 2013 Oct; 22(10):1107-14. PubMed ID: 23857864
[TBL] [Abstract][Full Text] [Related]
2. Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study.
Silverman SL; Siris E; Kendler DL; Belazi D; Brown JP; Gold DT; Lewiecki EM; Papaioannou A; Simonelli C; Ferreira I; Balasubramanian A; Dakin P; Ho P; Siddhanti S; Stolshek B; Recknor C
Osteoporos Int; 2015 Jan; 26(1):361-72. PubMed ID: 25236877
[TBL] [Abstract][Full Text] [Related]
3. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial.
Jamshidi A; Vojdanian M; Soroush M; Akbarian M; Aghaei M; Hajiabbasi A; Mirfeizi Z; Khabbazi A; Alishiri G; Haghighi A; Salimzadeh A; Karimzadeh H; Shirani F; Fard MRH; Nazarinia M; Soroosh S; Anjidani N; Gharibdoost F
Arthritis Res Ther; 2022 Jun; 24(1):161. PubMed ID: 35773713
[TBL] [Abstract][Full Text] [Related]
5. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
Josse R; Khan A; Ngui D; Shapiro M
Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
[TBL] [Abstract][Full Text] [Related]
6. Denosumab: a review of its use in postmenopausal women with osteoporosis.
Scott LJ
Drugs Aging; 2014 Jul; 31(7):555-76. PubMed ID: 24935243
[TBL] [Abstract][Full Text] [Related]
7. Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis.
Zhou Z; Chen C; Zhang J; Ji X; Liu L; Zhang G; Cao X; Wang P
Int J Clin Exp Pathol; 2014; 7(5):2113-22. PubMed ID: 24966919
[TBL] [Abstract][Full Text] [Related]
8. [Experience in using Prolia in patients with postmenopausal osteoporosis in clinical practice].
Skripnikova IA; Kosmatova OV; Abirova ES; Novikov VE; Murashko LM
Ter Arkh; 2017; 89(12. Vyp. 2):190-196. PubMed ID: 29488480
[TBL] [Abstract][Full Text] [Related]
9. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
Bone HG; Wagman RB; Brandi ML; Brown JP; Chapurlat R; Cummings SR; Czerwiński E; Fahrleitner-Pammer A; Kendler DL; Lippuner K; Reginster JY; Roux C; Malouf J; Bradley MN; Daizadeh NS; Wang A; Dakin P; Pannacciulli N; Dempster DW; Papapoulos S
Lancet Diabetes Endocrinol; 2017 Jul; 5(7):513-523. PubMed ID: 28546097
[TBL] [Abstract][Full Text] [Related]
10. [Austrian guidance for the pharmacologic treatment of osteoporosis in postmenopausal women: Addendum 2010].
Dimai HP; Pietschmann P; Resch H; Preisinger E; Fahrleitner-Pammer A; Dobnig H; Klaushofer K;
Wien Med Wochenschr; 2010 Dec; 160(21-22):586-9. PubMed ID: 21170699
[TBL] [Abstract][Full Text] [Related]
11. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
[TBL] [Abstract][Full Text] [Related]
12. Denosumab (prolia) for treatment of postmenopausal osteoporosis.
Johnson GL
Am Fam Physician; 2012 Feb; 85(4):334-6. PubMed ID: 22335312
[No Abstract] [Full Text] [Related]
13. Real-World Safety and Effectiveness of Denosumab in Patients with Osteoporosis: A Prospective, Observational Study in South Korea.
Rhee Y; Chang DG; Ha J; Kim S; Lee Y; Jo E; Koh JM
Endocrinol Metab (Seoul); 2022 Jun; 37(3):497-505. PubMed ID: 35654577
[TBL] [Abstract][Full Text] [Related]
14. Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension.
Watts NB; Brown JP; Papapoulos S; Lewiecki EM; Kendler DL; Dakin P; Wagman RB; Wang A; Daizadeh NS; Smith S; Bone HG
J Bone Miner Res; 2017 Jul; 32(7):1481-1485. PubMed ID: 28277603
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
[TBL] [Abstract][Full Text] [Related]
16. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis.
Moen MD; Keam SJ
Drugs Aging; 2011 Jan; 28(1):63-82. PubMed ID: 21174488
[TBL] [Abstract][Full Text] [Related]
17. Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy.
Rachner TD; Platzbecker U; Felsenberg D; Hofbauer LC
Mayo Clin Proc; 2013 Apr; 88(4):418-9. PubMed ID: 23541016
[TBL] [Abstract][Full Text] [Related]
18. Development and evaluation of an algorithm to identify users of Prolia(®) during the early postmarketing period using health insurance claims data.
Hoffman V; Xue F; Gardstein B; Skerry K; Critchlow CW; Enger C
Pharmacoepidemiol Drug Saf; 2014 Sep; 23(9):993-8. PubMed ID: 25052047
[TBL] [Abstract][Full Text] [Related]
19. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension.
Bone HG; Chapurlat R; Brandi ML; Brown JP; Czerwinski E; Krieg MA; Mellström D; Radominski SC; Reginster JY; Resch H; Ivorra JA; Roux C; Vittinghoff E; Daizadeh NS; Wang A; Bradley MN; Franchimont N; Geller ML; Wagman RB; Cummings SR; Papapoulos S
J Clin Endocrinol Metab; 2013 Nov; 98(11):4483-92. PubMed ID: 23979955
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada.
Chau D; Becker DL; Coombes ME; Ioannidis G; Adachi JD; Goeree R
J Med Econ; 2012; 15 Suppl 1():3-14. PubMed ID: 23035625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
